0001209191-23-045879.txt : 20230815
0001209191-23-045879.hdr.sgml : 20230815
20230815165557
ACCESSION NUMBER: 0001209191-23-045879
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230813
FILED AS OF DATE: 20230815
DATE AS OF CHANGE: 20230815
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Willoughby Scott B.
CENTRAL INDEX KEY: 0001877368
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 231175576
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-13
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001877368
Willoughby Scott B.
C/O SANGAMO THERAPEUTICS, INC.
7000 MARINA BLVD.
BRISBANE
CA
94005
0
1
0
0
SVP, Gen. Counsel & Secretary
0
Common Stock
2023-08-13
4
F
0
864
1.08
D
129420
D
Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 13, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 11, 2023 of $1.08/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
Includes: (a) 1,636 shares resulting from the August 13, 2023 vesting installment of the Reporting Person's August 13, 2021 RSU grant and 2,500 shares subject to such RSU grant that will vest in one final installment on August 13, 2024, (b) 26,907 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (see footnote 3)
(d) 42,750 shares subject to the Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Includes 5,000 shares acquired on May 31, 2023 under the Issuer's 2020 Employee Stock Purchase Plan.
Scott B. Willoughby, by /s/ Ron A. Metzger, Attorney-in-Fact
2023-08-15